Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075009 · ClinicalTrials.gov registry record
Predictors of Rates of Resistant Gram-Negative Bacteria
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 36
- Enrollment target
NCT01075009 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 36 participants.
The verdict
NCT01075009 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Antibiotic resistance in gram-negative bacteria continues to increase in US hospitals. This comes at a time when there are few new drugs in development that are active for these resistant organisms. The implication is that we must learn to use the drugs that we have more wisely and develop new strategies that will preserve existing agents. Antimicrobial "stewardship" programs are one strategy that many hospitals are adopting to improve the quality of antimicrobial use. The goal of this project is to develop a consortium of US academic medical centers that will allow characterization of the relationships between antibiotic use and rates of resistance for gram-negative pathogens, and to help hospital devise new strategies that will modify antibiotic use and possibly delay or reduce resistance. The specific hypotheses are: * Hospitals with established or emerging resistance in gram-negative pathogens, including extended spectrum beta-lactamase (ESBL) producing organisms, carbapenem-resistant enterobacteriaceae (CRE)and carbapenem-resistant P. aeruginosa have a different pattern of antimicrobial drug use compared to hospitals with fewer of these organisms. * Hospital use of ertapenem is not associated with the rates of carbapenem-resistant organisms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01075009
The ClinicalTrials.gov registry entry for NCT01075009 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01075009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01075009 about?
NCT01075009 is a clinical study titled "Predictors of Rates of Resistant Gram-Negative Bacteria". Antibiotic resistance in gram-negative bacteria continues to increase in US hospitals. This comes at a time when there are few new drugs in development that are active for these resistant organisms. The implication is that we must learn to use the drugs that we have more wisely and develop new strat...
What is the current status of trial NCT01075009?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2010-02. Estimated completion is 2013-05.
Who is sponsoring clinical trial NCT01075009?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.